Filing Flows › Biomerica (BMRA) › Q1 FY26
Biomerica (BMRA) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Oct 14, 2025
Biomerica (BMRA) reported revenue of $1.4M for the first quarter fiscal 2026 (Q1 FY26), -24% from a year earlier and +84% from the quarter before. Operating margin was -81.0%, net earnings $2K (0.1% of revenue).
Biomerica, Q1 FY26: revenue $1.4M (-24% year over year), operating margin -81.0%, net earnings $2K, operating cash flow −$268K. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | +84% | -24% |
| Operating profit | −$1.1M | — | — |
| Net earnings | $2K | — | — |
| Operating cash flow | −$268K | — | — |
What changed
Revenue was $1.4M in Q1 FY26, down 24% year over year and up 84% from the previous quarter. Clinical Lab was the largest line at 74% of revenue. Clinical Lab lost $254K year over year (down 20%), 59% of the total change.
Gross margin was 30.7%, up 14.7 points from a year earlier. Operating costs exceeded revenue by $1.1M, an operating margin of -81.0%. Operating expenses fell 7% while revenue fell 24%. Net earnings were $2K. The effective tax rate was 60.0%. Non-operating items added $1.1M, 22460% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$268K. Non-cash charges added back $20K of depreciation and amortization and $133K of share-based compensation. Working capital and other items used $423K.
Questions
What was Biomerica's revenue in the first quarter fiscal 2026?
Biomerica (BMRA) reported revenue of $1.4M for the first quarter fiscal 2026 (Q1 FY26), -24% from a year earlier and +84% from the quarter before.
Was Biomerica profitable in the first quarter fiscal 2026?
Operating loss was $1.1M (-81.0% of revenue) and net earnings $2K.
Source: Biomerica 10-Q on SEC EDGAR.